Peptide therapy cost in 2026: clinics, compounding and vendors

There are three ways to get a peptide, each with its own price structure. A clinic or telehealth protocol bundles a consult, a prescription where one is legally possible, the product and some follow up into a monthly fee. A compounding pharmacy fills a prescription for a named patient. A research vendor sells lyophilized powder with no prescription and no claim it is meant for people. How to buy peptides explains which compounds can legally travel each route.

The table gives the ranges that appear most often in 2026 marketing and vendor listings, as commonly quoted figures rather than what you will pay. The one consistent pattern is the order: branded drug at list price costs the most, clinic protocols next, compounded prescriptions next, research vials least.

A typical clinic protocol is priced as a monthly membership or a per protocol fee, and the 200 to 600 dollar range is where most quotes land. The lower end usually buys a single compound at a low dose with a telehealth check in. The upper end buys a GLP-1 drug, a second compound, or in person visits. Peptide clinics are cash pay businesses, and two clinics quoting the same compound can be hundreds of dollars apart.

Several things are billed separately. An initial consult of 100 to 300 dollars is standard. Baseline labs are usually required and often quoted at a hundred to a few hundred dollars for a metabolic panel, lipids, HbA1c and sometimes hormones, with repeat labs every few months. Shipping, supplies and dose increases each add to the bill, and a protocol that starts at 300 a month can cost 450 by month four once the dose has climbed.

What the fee buys depends on the compound. For an approved drug like semaglutide or tirzepatide, it buys a prescription, a labeled pharmacy product, and a prescriber watching for the problems the side effects article lists. For a compound that cannot legally be compounded in the US, such as BPC-157, the clinic is sourcing research grade material and the fee mostly buys the consultation.

Compounded tirzepatide through a telehealth service is the most searched single price here, commonly quoted at roughly 250 to 400 dollars a month. Compounded semaglutide tends to be quoted somewhat lower. The price usually scales with dose because a higher dose means a larger vial or more of them, and quotes often advertise the cheaper starting month. The tirzepatide dosage chart and semaglutide dosage chart show how many mg a month each label step uses.

Lilly's self pay Zepbound vials, sold outside insurance, are commonly quoted at roughly 349 to 499 dollars a month depending on the dose. That puts an approved, sterile product within a hundred or so dollars of a compounded version, a much narrower gap than two years ago. The FDA proposed removing these drugs from the 503B bulks list in April 2026, and if that is finalized, the compounded price point may disappear for many people.

A research vendor sells a vial of powder. On our September 2026 price snapshot, the vendors tracked on the compare page listed a 30 mg tirzepatide vial at roughly 55 to 135 dollars and a 10 mg retatrutide vial at roughly 30 to 80 dollars. Listed prices move weekly, so check the live page.

The price is low because almost nothing is included: no prescription, no pharmacist, no sterility guarantee, no endotoxin test unless the COA shows one, no labeled concentration until you add the water yourself, and no one to call if something goes wrong. The cost of supervision has not gone away. It has moved to the buyer, who either pays for labs and a clinician separately or does without. This is also the only route for compounds with no legal prescription path, such as BPC-157 and TB-500, and the vendor reviews cover who publishes testing.

Insurers pay for approved drugs prescribed for approved indications, and nearly everything on this site fails one half of that test. Research peptides are not approved drugs. Compounded products are not either, even when the active ingredient is one, and plans generally exclude them. Clinic protocol fees are a service, not a drug claim.

Even the approved GLP-1 drugs are inconsistent. Medicare Part D has excluded weight loss drugs by statute since the program began, although coverage exists for the diabetes versions and for semaglutide's cardiovascular indication. Commercial plans range from full coverage to a flat exclusion. That inconsistency pushed many people to compounded and research products, and it is why the cost question is mostly a cash question.

Three variables explain most of the spread. The first is the compound. GLP-1 class drugs are long, lipidated peptides that are harder to synthesize than a five amino acid chain, and they carry the demand premium of the most searched compounds on the internet. A month of retatrutide costs more than a month of BPC-157 because it costs more to make and more people want it.

The second is dose. Vials are priced per vial, so the monthly cost is the price per mg times the mg used in a month. Semaglutide at 2.4 mg weekly uses about 10 mg a month; tirzepatide at 10 mg weekly about 43 mg; retatrutide at 8 mg weekly about 35 mg. A dose increase on the label is a price increase in the vial, and a reconstituted vial has to be used within about 4 weeks, so a vial larger than a month of doses wastes the remainder.

The third is vial size. Price per mg falls as the vial grows: on the September 2026 snapshot, a 20 mg retatrutide vial cost less per mg than two 10 mg vials at nearly every vendor. That collides with the 4 week window, since at a low dose a large vial can expire before it is used. The calculator shows how long a vial lasts at a given dose.

Cost per mg is the right unit: price divided by the mg on the label. The problem is the second number. A label that says 10 mg is a claim, and on the grey market it is rarely tested. An HPLC purity figure tells you what fraction of the peptide present is the right molecule, not how much peptide is in the vial. Only a quantitative assay does that, and how to read a COA explains why most vendors skip it.

So an honest comparison has four lines, not one: price per labeled mg, whether the vendor has quantity testing behind the label, waste from the 4 week window at your dose, and the cost of what the route leaves out. For approved products the comparison is cleaner, because the mg on a Zepbound vial is the mg in it, and that is the main thing the extra money buys.

A price well below the rest of the market is information. Peptide synthesis has a floor cost. A vendor selling a 39 amino acid lipidated peptide for a fraction of what every competitor charges is running a loss leader, selling an underfilled or lower purity vial, or selling something that is not the compound on the label. Underfilling is the most common and the hardest to detect without a quantitative assay, which is exactly the test the cheapest vendors skip.

The practical risk follows the compound. An underfilled BPC-157 vial wastes money. An underfilled or mislabeled GLP-1 vial changes the dose, and a weak vial followed by a full strength one can land someone on a jump the label would never allow. The are peptides safe article covers contamination and identity. The cheapest listed price is only the cheapest if the vial contains what it says, and the way to know is a certificate, not a price tag.